EquitySector - HealthcareVery High Risk
Regular
NAV (27-Mar-25)
Returns (Since Inception)
Fund Size
₹4,611 Cr
Expense Ratio
1.94%
ISIN
INF109KC1GE9
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
12 Jul 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+21.83%
+17.95% (Cat Avg.)
3 Years
+22.95%
+18.51% (Cat Avg.)
5 Years
+31.71%
+28.12% (Cat Avg.)
Since Inception
+21.24%
— (Cat Avg.)
Equity | ₹4,567.22 Cr | 99.04% |
Others | ₹44.25 Cr | 0.96% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹609.3 Cr | 13.21% |
Cipla Ltd | Equity | ₹440.33 Cr | 9.55% |
Dr Reddy's Laboratories Ltd | Equity | ₹412.27 Cr | 8.94% |
Divi's Laboratories Ltd | Equity | ₹312.72 Cr | 6.78% |
Aurobindo Pharma Ltd | Equity | ₹237.58 Cr | 5.15% |
Lupin Ltd | Equity | ₹218.2 Cr | 4.73% |
Alkem Laboratories Ltd | Equity | ₹206.95 Cr | 4.49% |
Gland Pharma Ltd | Equity | ₹162.29 Cr | 3.52% |
Zydus Lifesciences Ltd | Equity | ₹150.68 Cr | 3.27% |
Mankind Pharma Ltd | Equity | ₹131.29 Cr | 2.85% |
Apollo Hospitals Enterprise Ltd | Equity | ₹126.77 Cr | 2.75% |
SBI Life Insurance Co Ltd | Equity | ₹96.18 Cr | 2.09% |
Syngene International Ltd | Equity | ₹88.13 Cr | 1.91% |
Pfizer Ltd | Equity | ₹87.99 Cr | 1.91% |
Atul Ltd | Equity | ₹82.13 Cr | 1.78% |
AstraZeneca Pharma India Ltd | Equity | ₹78.91 Cr | 1.71% |
Treps | Cash - Repurchase Agreement | ₹78.44 Cr | 1.70% |
Medplus Health Services Ltd | Equity | ₹71.24 Cr | 1.54% |
Medi Assist Healthcare Services Ltd | Equity | ₹66.05 Cr | 1.43% |
Windlas Biotech Ltd | Equity | ₹65.44 Cr | 1.42% |
Advanced Enzyme Technologies Ltd | Equity | ₹65.25 Cr | 1.41% |
Alembic Pharmaceuticals Ltd | Equity | ₹64.75 Cr | 1.40% |
Biocon Ltd | Equity | ₹62.82 Cr | 1.36% |
Shilpa Medicare Ltd | Equity | ₹58.76 Cr | 1.27% |
Fine Organic Industries Ltd Ordinary Shares | Equity | ₹52.63 Cr | 1.14% |
Thyrocare Technologies Ltd | Equity | ₹51.5 Cr | 1.12% |
Aarti Industries Ltd | Equity | ₹49.61 Cr | 1.08% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹48.8 Cr | 1.06% |
Aarti Drugs Ltd | Equity | ₹48.67 Cr | 1.06% |
Glenmark Pharmaceuticals Ltd | Equity | ₹48.45 Cr | 1.05% |
FDC Ltd | Equity | ₹45.74 Cr | 0.99% |
Net Current Assets | Cash | ₹-42.6 Cr | 0.92% |
Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹40.98 Cr | 0.89% |
Procter & Gamble Health Ltd | Equity | ₹39.27 Cr | 0.85% |
Senores Pharmaceuticals Ltd | Equity | ₹34.92 Cr | 0.76% |
Star Health and Allied Insurance Co Ltd | Equity | ₹33.95 Cr | 0.74% |
Sun Pharma Advanced Research Co Ltd | Equity | ₹31.33 Cr | 0.68% |
Fortis Healthcare Ltd | Equity | ₹30.71 Cr | 0.67% |
Emcure Pharmaceuticals Ltd | Equity | ₹29.22 Cr | 0.63% |
Alivus Life Sciences Ltd | Equity | ₹20 Cr | 0.43% |
Blue Jet Healthcare Ltd | Equity | ₹19.37 Cr | 0.42% |
Unichem Laboratories Ltd | Equity | ₹15.78 Cr | 0.34% |
Laxmi Dental Ltd | Equity | ₹13.81 Cr | 0.30% |
Laxmi Organic Industries Ltd | Equity | ₹11.14 Cr | 0.24% |
Cash Margin - Derivatives | Cash - Collateral | ₹8.41 Cr | 0.18% |
Galaxy Surfactants Ltd | Equity | ₹5.31 Cr | 0.12% |
Large Cap Stocks
43.84%
Mid Cap Stocks
24.96%
Small Cap Stocks
29.95%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹4,171.03 Cr | 90.45% |
Basic Materials | ₹266.06 Cr | 5.77% |
Financial Services | ₹130.13 Cr | 2.82% |
Standard Deviation
This fund
16.04%
Cat. avg.
16.58%
Lower the better
Sharpe Ratio
This fund
0.92
Cat. avg.
0.70
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.18
Higher the better
Since May 2020
Since July 2022
ISIN INF109KC1GE9 | Expense Ratio 1.94% | Exit Load 1.00% | Fund Size ₹4,611 Cr | Age 6 years 8 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹25.63 Cr | 20.0% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.1% | 1.0% | ₹754.75 Cr | 13.4% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹754.75 Cr | 11.9% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹37.95 Cr | 15.9% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹200.83 Cr | 19.0% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹200.83 Cr | 16.8% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2441.13 Cr | 19.9% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹2441.13 Cr | 18.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹809.18 Cr | 13.8% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹17.44 Cr | 15.8% |
Total AUM
₹9,02,856 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Regular
NAV (27-Mar-25)
Returns (Since Inception)
Fund Size
₹4,611 Cr
Expense Ratio
1.94%
ISIN
INF109KC1GE9
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
12 Jul 2018
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+21.83%
+17.95% (Cat Avg.)
3 Years
+22.95%
+18.51% (Cat Avg.)
5 Years
+31.71%
+28.12% (Cat Avg.)
Since Inception
+21.24%
— (Cat Avg.)
Equity | ₹4,567.22 Cr | 99.04% |
Others | ₹44.25 Cr | 0.96% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹609.3 Cr | 13.21% |
Cipla Ltd | Equity | ₹440.33 Cr | 9.55% |
Dr Reddy's Laboratories Ltd | Equity | ₹412.27 Cr | 8.94% |
Divi's Laboratories Ltd | Equity | ₹312.72 Cr | 6.78% |
Aurobindo Pharma Ltd | Equity | ₹237.58 Cr | 5.15% |
Lupin Ltd | Equity | ₹218.2 Cr | 4.73% |
Alkem Laboratories Ltd | Equity | ₹206.95 Cr | 4.49% |
Gland Pharma Ltd | Equity | ₹162.29 Cr | 3.52% |
Zydus Lifesciences Ltd | Equity | ₹150.68 Cr | 3.27% |
Mankind Pharma Ltd | Equity | ₹131.29 Cr | 2.85% |
Apollo Hospitals Enterprise Ltd | Equity | ₹126.77 Cr | 2.75% |
SBI Life Insurance Co Ltd | Equity | ₹96.18 Cr | 2.09% |
Syngene International Ltd | Equity | ₹88.13 Cr | 1.91% |
Pfizer Ltd | Equity | ₹87.99 Cr | 1.91% |
Atul Ltd | Equity | ₹82.13 Cr | 1.78% |
AstraZeneca Pharma India Ltd | Equity | ₹78.91 Cr | 1.71% |
Treps | Cash - Repurchase Agreement | ₹78.44 Cr | 1.70% |
Medplus Health Services Ltd | Equity | ₹71.24 Cr | 1.54% |
Medi Assist Healthcare Services Ltd | Equity | ₹66.05 Cr | 1.43% |
Windlas Biotech Ltd | Equity | ₹65.44 Cr | 1.42% |
Advanced Enzyme Technologies Ltd | Equity | ₹65.25 Cr | 1.41% |
Alembic Pharmaceuticals Ltd | Equity | ₹64.75 Cr | 1.40% |
Biocon Ltd | Equity | ₹62.82 Cr | 1.36% |
Shilpa Medicare Ltd | Equity | ₹58.76 Cr | 1.27% |
Fine Organic Industries Ltd Ordinary Shares | Equity | ₹52.63 Cr | 1.14% |
Thyrocare Technologies Ltd | Equity | ₹51.5 Cr | 1.12% |
Aarti Industries Ltd | Equity | ₹49.61 Cr | 1.08% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹48.8 Cr | 1.06% |
Aarti Drugs Ltd | Equity | ₹48.67 Cr | 1.06% |
Glenmark Pharmaceuticals Ltd | Equity | ₹48.45 Cr | 1.05% |
FDC Ltd | Equity | ₹45.74 Cr | 0.99% |
Net Current Assets | Cash | ₹-42.6 Cr | 0.92% |
Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹40.98 Cr | 0.89% |
Procter & Gamble Health Ltd | Equity | ₹39.27 Cr | 0.85% |
Senores Pharmaceuticals Ltd | Equity | ₹34.92 Cr | 0.76% |
Star Health and Allied Insurance Co Ltd | Equity | ₹33.95 Cr | 0.74% |
Sun Pharma Advanced Research Co Ltd | Equity | ₹31.33 Cr | 0.68% |
Fortis Healthcare Ltd | Equity | ₹30.71 Cr | 0.67% |
Emcure Pharmaceuticals Ltd | Equity | ₹29.22 Cr | 0.63% |
Alivus Life Sciences Ltd | Equity | ₹20 Cr | 0.43% |
Blue Jet Healthcare Ltd | Equity | ₹19.37 Cr | 0.42% |
Unichem Laboratories Ltd | Equity | ₹15.78 Cr | 0.34% |
Laxmi Dental Ltd | Equity | ₹13.81 Cr | 0.30% |
Laxmi Organic Industries Ltd | Equity | ₹11.14 Cr | 0.24% |
Cash Margin - Derivatives | Cash - Collateral | ₹8.41 Cr | 0.18% |
Galaxy Surfactants Ltd | Equity | ₹5.31 Cr | 0.12% |
Large Cap Stocks
43.84%
Mid Cap Stocks
24.96%
Small Cap Stocks
29.95%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹4,171.03 Cr | 90.45% |
Basic Materials | ₹266.06 Cr | 5.77% |
Financial Services | ₹130.13 Cr | 2.82% |
Standard Deviation
This fund
16.04%
Cat. avg.
16.58%
Lower the better
Sharpe Ratio
This fund
0.92
Cat. avg.
0.70
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.18
Higher the better
Since May 2020
Since July 2022
ISIN INF109KC1GE9 | Expense Ratio 1.94% | Exit Load 1.00% | Fund Size ₹4,611 Cr | Age 6 years 8 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹25.63 Cr | 20.0% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.1% | 1.0% | ₹754.75 Cr | 13.4% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹754.75 Cr | 11.9% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹37.95 Cr | 15.9% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹200.83 Cr | 19.0% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹200.83 Cr | 16.8% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2441.13 Cr | 19.9% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹2441.13 Cr | 18.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹809.18 Cr | 13.8% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹17.44 Cr | 15.8% |
Total AUM
₹9,02,856 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments